The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test.
The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co. Inc. to treat mild-to-moderate Covid-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for U.S. emergency use authorization.
AstraZeneca’s antibody cocktail against Covid-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
Merck has submitted data to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA) for the company’s antiviral pill molnupiravir.
Two Indian drugmakers requested permission to end their late-stage trials on Merck & Co.’s experimental antiviral drug molnupiravir in moderate Covid-19 patients.
Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.
Interim results from the Phase III trial of a potential treatment for mild-to-moderate Covid-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening the company’s portfolio beyond the aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
Laboratory studies show that Merck & Co.’s experimental oral Covid-19 antiviral drug molnupiravir is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Sept. 29.
As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.